샘플 요청 목록

 카트 문의
시장보고서
상품코드
1785841

세계의 바이오마커 임상 단계 아웃소싱 서비스 시장

Biomarker Clinical Phase Outsourcing Services
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 186 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 바이오마커 임상 단계 아웃소싱 서비스 시장은 2030년까지 287억 달러에 이를 전망

2024년에 92억 달러로 추정되는 바이오마커 임상 단계 아웃소싱 서비스 세계 시장은 2024-2030년의 분석 기간에 CAGR 20.8%로 성장하여 2030년에는 287억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 예측 바이오마커는 CAGR 20.2%를 나타내고, 분석 기간 종료까지 110억 달러에 이를 것으로 예측됩니다. 예후 바이오마커 분야의 성장률은 분석 기간중 CAGR 21.9%로 추정됩니다.

미국 시장은 24억 달러, 중국은 CAGR19.7%를 보일 것으로 예측

미국의 바이오마커 임상 단계 아웃소싱 서비스 시장은 2024년에는 24억 달러에 이를 것으로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 44억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 19.7%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 18.9%와 18.1%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 15.0%를 보일 전망입니다.

세계의 바이오마커 임상 단계 아웃소싱 서비스 시장 - 주요 동향과 촉진요인 정리

바이오마커 임상 단계 아웃소싱 서비스에 대한 수요가 증가하는 이유는 무엇일까?

정밀의료와 표적치료의 급속한 확대로 바이오마커 기반 임상시험에 대한 수요가 크게 증가함에 따라 제약기업과 바이오테크 기업이 바이오마커 개발의 주요 단계를 아웃소싱하게 되었습니다. 바이오마커 임상 단계 아웃소싱 서비스는 바이오마커 검증, 환자 계층화, 생물학적 분석 시험, 규제 준수 지원 등 다양한 기능을 포괄합니다. 의약품 개발 프로세스가 점점 더 복잡해지고 데이터 중심화됨에 따라, 이러한 중요한 단계를 전문 CRO에 아웃소싱하는 것은 업무를 간소화하고 시장 출시 시간을 단축하는 데 필수적인 전략이 되고 있습니다. 또한, 암, 신경퇴행성 질환, 심혈관 질환 등 만성질환의 유행이 확대됨에 따라 바이오마커를 활용한 진단 및 치료 솔루션의 필요성이 높아지고 있습니다. 바이오마커는 질병의 진행을 예측하고, 치료 효과를 평가하고, 부작용을 최소화하는 데 중요한 역할을 하기 때문에 최신 임상시험에 필수적인 요소로 자리 잡고 있습니다. 제약사들이 고도로 맞춤화된 치료법을 개발하기 위해 노력하면서 바이오마커 서비스 아웃소싱에 대한 수요가 급증하고 있으며, 전문 지식을 갖춘 CRO의 인프라와 규제 당국 대응 능력을 활용할 수 있게 되었습니다.

기술 발전은 바이오마커 아웃소싱 서비스를 어떻게 변화시키고 있는가?

기술 혁신은 바이오마커 아웃소싱의 상황을 바꾸고 있으며, 보다 신속하고 정확하며 비용 효율적인 임상시험을 가능하게 하고 있습니다. 유전체학, 단백질체학, 대사체학의 발전으로 새로운 바이오마커가 발견되어 질병의 조기 발견과 치료 모니터링이 향상되고 있습니다. AI와 머신러닝은 바이오마커 데이터 분석을 더욱 강화하여 연구자들이 방대한 데이터 세트에서 의미 있는 패턴과 상관관계를 찾아내어 환자 선택을 최적화하고 임상시험 성공률을 높일 수 있도록 돕고 있습니다. 또한, 바이오마커 분석에서 차세대 염기서열 분석(NGS)과 디지털 병리학(Digital Pathology)의 통합은 질병 메커니즘에 대한 보다 정확한 통찰력을 제공합니다. 이러한 기술은 동반진단의 효율성을 향상시키고 표적치료제 개발을 강화하고 있습니다. 또한, 바이오마커를 기반으로 한 임상시험에서 액체생검 기술의 활용이 확산되고 있어 저침습적인 시술로 질병의 진행을 실시간으로 모니터링할 수 있게 되었습니다. 이러한 기술 발전이 바이오마커 개발을 계속 형성함에 따라 아웃소싱 서비스는 점점 더 고도화되어 제약 및 생명공학 기업에 보다 종합적이고 맞춤형 솔루션을 제공합니다.

바이오마커 임상 단계 아웃소싱 서비스의 성장을 가속하는 시장 동향은?

바이오마커 아웃소싱 시장을 형성하는 가장 두드러진 트렌드 중 하나는 맞춤형 의료에 대한 관심이 높아지고 있다는 점입니다. 헬스케어가 획일적인 접근 방식에서 보다 개인화된 치료 전략으로 전환함에 따라 바이오마커 기반 의약품 개발의 필요성이 증가하고 있습니다. 제약사들은 바이오마커 아웃소싱 서비스를 활용하여 특정 치료법이 가장 효과적이라고 생각되는 환자군을 식별하는 특수한 임상시험을 수행하여 치료 성과 향상과 허가 가능성을 높이고 있습니다. 또 다른 중요한 시장 동향은 분산형 임상시험과 가상 임상시험의 부상입니다. 디지털 헬스 기술과 원격 환자 모니터링의 발전으로 바이오마커 연구는 전통적인 임상 환경을 넘어 확장되고 있습니다. CRO는 원격 바이오마커 수집, AI 기반 분석, 클라우드 기반 데이터 관리 솔루션을 제공하여 위탁 임상시험 단계의 효율성과 접근성을 높이고 있습니다. 또한, FDA 및 EMA와 같은 규제 기관은 바이오마커 중심의 의약품 승인을 추진하고 있으며, 이는 제약사들이 바이오마커 검증 및 검사 서비스 아웃소싱에 투자하는 것을 더욱 촉진하고 있습니다.

바이오마커 임상 단계 아웃소싱 서비스 시장의 주요 성장 촉진요인은 무엇인가?

바이오마커 임상 단계 아웃소싱 서비스 시장의 성장은 임상시험의 복잡성 증가, 개인 맞춤형 의료에 대한 수요 증가, 바이오마커 조사 기술의 발전 등 여러 요인에 의해 이루어지고 있습니다. 바이오마커 개발은 높은 비용과 리소스를 필요로 하는 특성상, 의약품 파이프라인을 최적화하고 업무 부담을 줄이고자 하는 제약사에게 아웃소싱은 매력적인 선택이 될 수 있습니다. 또한, 임상시험의 세계화도 시장 확대에 기여하고 있습니다. 아웃소싱을 통해 제약사는 규제 요건을 준수하면서 여러 지역에서 바이오마커 연구를 수행할 수 있기 때문입니다. 또한, 바이오마커 연구에 AI와 빅데이터 분석의 도입이 확대되면서 데이터 분석의 간소화와 임상시험의 효율성이 높아지고 있습니다. 정밀의료와 바이오마커 탐색의 끊임없는 혁신에 따라 바이오마커 임상단계 서비스 아웃소싱 시장은 비약적인 성장이 예상되며, CRO는 의약품 개발 및 개인 맞춤형 헬스케어의 미래에 필수적인 파트너로 자리매김하고 있습니다.

부문

바이오마커 유형(예측 바이오마커, 예후 바이오마커, 안전성 바이오마커, 대체 엔드포인트), 치료 영역(암 치료 영역, 신경 치료 영역, 순환기 치료 영역, 자가면역질환 치료 영역, 기타 치료 영역), 최종사용자(바이오테크놀러지 기업 최종사용자, 제약 기업 최종사용자, 기타 최종사용자)

조사 대상 기업 예

  • Celerion
  • Charles River Laboratories
  • Clario
  • Eurofins Scientific SE
  • GenScript Biotech Corporation
  • ICON Plc
  • IQVIA
  • Laboratory Corporation of America Holdings
  • NorthEast BioAnalytical Laboratories LLC
  • Parexel International Corporation
  • Proteome Sciences
  • Syneos Health

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

LSH 25.08.14

Global Biomarker Clinical Phase Outsourcing Services Market to Reach US$28.7 Billion by 2030

The global market for Biomarker Clinical Phase Outsourcing Services estimated at US$9.2 Billion in the year 2024, is expected to reach US$28.7 Billion by 2030, growing at a CAGR of 20.8% over the analysis period 2024-2030. Predictive Biomarkers, one of the segments analyzed in the report, is expected to record a 20.2% CAGR and reach US$11.0 Billion by the end of the analysis period. Growth in the Prognostic Biomarkers segment is estimated at 21.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 19.7% CAGR

The Biomarker Clinical Phase Outsourcing Services market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.4 Billion by the year 2030 trailing a CAGR of 19.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.9% and 18.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.0% CAGR.

Global Biomarker Clinical Phase Outsourcing Services Market - Key Trends & Drivers Summarized

Why Is the Demand for Biomarker Clinical Phase Outsourcing Services Rising?

The rapid expansion of precision medicine and targeted therapies has significantly increased the need for biomarker-based clinical trials, leading pharmaceutical and biotechnology companies to outsource key phases of biomarker development. Biomarker clinical phase outsourcing services encompass a wide range of functions, including biomarker validation, patient stratification, bioanalytical testing, and regulatory compliance support. As drug development processes become more complex and data-driven, outsourcing these critical phases to specialized contract research organizations (CROs) is becoming an essential strategy to streamline operations and accelerate time-to-market. Additionally, the growing prevalence of chronic diseases such as cancer, neurodegenerative disorders, and cardiovascular conditions has fueled the need for biomarker-driven diagnostics and therapeutic solutions. Biomarkers play a crucial role in predicting disease progression, assessing treatment responses, and minimizing adverse effects, making them indispensable for modern clinical trials. As pharmaceutical companies strive to develop highly personalized treatment regimens, the demand for outsourced biomarker services is surging, allowing them to leverage the expertise, infrastructure, and regulatory proficiency of specialized CROs.

How Are Technological Advancements Transforming Biomarker Outsourcing Services?

Technological innovations are revolutionizing the biomarker outsourcing landscape, enabling faster, more accurate, and cost-effective clinical phase studies. Advances in genomics, proteomics, and metabolomics have led to the discovery of novel biomarkers, improving early disease detection and therapeutic monitoring. AI and machine learning are further enhancing biomarker data analysis, allowing researchers to identify meaningful patterns and correlations from vast datasets, optimizing patient selection, and improving trial success rates. Moreover, the integration of next-generation sequencing (NGS) and digital pathology in biomarker analysis is providing more precise insights into disease mechanisms. These technologies are improving the efficiency of companion diagnostics and enhancing the development of targeted therapies. Additionally, the use of liquid biopsy techniques is gaining traction in biomarker-based clinical trials, allowing for real-time monitoring of disease progression through minimally invasive procedures. As these technological advancements continue to shape biomarker development, outsourcing services are becoming increasingly sophisticated, offering more comprehensive and tailored solutions for pharmaceutical and biotech companies.

What Market Trends Are Driving the Growth of Biomarker Clinical Phase Outsourcing Services?

One of the most prominent trends shaping the biomarker outsourcing market is the increasing focus on personalized medicine. As healthcare shifts from a one-size-fits-all approach to more individualized treatment strategies, the need for biomarker-driven drug development has intensified. Pharmaceutical firms are leveraging biomarker outsourcing services to conduct specialized clinical trials that identify patient subgroups most likely to benefit from specific therapies, improving treatment outcomes and regulatory approval chances. Another key market trend is the rise of decentralized and virtual clinical trials. With advancements in digital health technologies and remote patient monitoring, biomarker research is expanding beyond traditional clinical settings. CROs are increasingly offering remote biomarker collection, AI-driven analytics, and cloud-based data management solutions, enhancing the efficiency and accessibility of outsourced clinical trial phases. Furthermore, regulatory agencies such as the FDA and EMA are promoting biomarker-driven drug approvals, further encouraging pharmaceutical companies to invest in outsourced biomarker validation and testing services.

What Are the Key Growth Drivers for the Biomarker Clinical Phase Outsourcing Services Market?

The growth in the Biomarker Clinical Phase Outsourcing Services market is driven by several factors, including the increasing complexity of clinical trials, rising demand for personalized medicine, and advancements in biomarker research technologies. The high costs and resource-intensive nature of biomarker development have made outsourcing an attractive option for pharmaceutical companies seeking to optimize their drug pipelines and reduce operational burdens. The globalization of clinical trials is also contributing to market expansion, as outsourcing enables pharmaceutical firms to conduct multi-regional biomarker studies while ensuring compliance with regulatory requirements. Additionally, the growing adoption of AI and big data analytics in biomarker research is streamlining data interpretation and improving clinical trial efficiencies. With continuous innovations in precision medicine and biomarker discovery, the market for outsourced biomarker clinical phase services is expected to witness exponential growth, positioning CROs as indispensable partners in the future of drug development and personalized healthcare.

SCOPE OF STUDY:

The report analyzes the Biomarker Clinical Phase Outsourcing Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Biomarker Type (Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, Surrogate Endpoints); Therapeutic Area (Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area, Other Therapeutic Areas); End-Use (Biotechnology Companies End-Use, Pharmaceutical Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 48 Featured) -

  • Celerion
  • Charles River Laboratories
  • Clario
  • Eurofins Scientific SE
  • GenScript Biotech Corporation
  • ICON Plc
  • IQVIA
  • Laboratory Corporation of America Holdings
  • NorthEast BioAnalytical Laboratories LLC
  • Parexel International Corporation
  • Proteome Sciences
  • Syneos Health

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Biomarker Clinical Phase Outsourcing Services - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in Biomarker-Driven Drug Development Pipelines Throws the Spotlight on Clinical Phase Outsourcing Services
    • Rising Complexity of Multimodal Biomarkers Drives Demand for Specialized Clinical Validation Expertise
    • Increased Use of Companion Diagnostics in Oncology Spurs Outsourcing of Biomarker-Enriched Trials
    • Regulatory Push for Stratified Trial Designs Strengthens Business Case for Biomarker-Driven Patient Segmentation
    • Expansion of Immunotherapy and Precision Medicine Trials Accelerates Need for Outsourced Biomarker Operations
    • Growth in Liquid Biopsy and Non-Invasive Monitoring Platforms Fuels Demand for Flexible Clinical Trial Models
    • OEM Focus on Accelerating Time-to-IND and Time-to-Approval Drives Adoption of Biomarker CRO Partnerships
    • Emergence of Multi-Omic and Digital Biomarkers Expands Technical Capabilities Required From Service Providers
    • Increased Integration of Central Lab and Site Network Services Enhances Operational Continuity in Biomarker Trials
    • Use of AI for Adaptive Trial Design and Endpoint Prediction Supports Outsourced Biomarker Optimization
    • Rise in Real-World Evidence and Post-Market Studies Reinforces Role of Biomarkers in Longitudinal Monitoring
    • Globalization of Multicenter Trials Promotes Outsourcing of Biomarker Logistics and Compliance Management
    • OEM Partnerships With Bioinformatics Firms Enhance Clinical Interpretation of High-Dimensional Biomarker Data
    • Regulatory Harmonization Across FDA, EMA, and PMDA Supports Outsourced Global Biomarker Development
    • Increasing Use of Circulating Tumor DNA and RNA Biomarkers Drives Sample Handling and Data Processing Outsourcing
    • OEM Demand for Centralized Data Platforms and Biomarker Traceability Strengthens Outsourced Model Preference
    • Growth in Rare Disease Trials and Niche Patient Populations Fuels Biomarker-Centric Outsourcing Models
    • OEM Investment in Risk-Based Monitoring and Decentralized Trials Expands Biomarker Data Capture Models
    • Availability of Qualified Biomarker Banks and Retrospective Analysis Services Supports Late-Phase Trial Value
    • Cost-Containment and Operational Efficiency Objectives Drive Long-Term Outsourcing in Biomarker-Enriched Clinical Trials
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Predictive Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Predictive Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Prognostic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for Prognostic Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Safety Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Safety Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Surrogate Endpoints by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for Surrogate Endpoints by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Oncology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Neurology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Neurology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Cardiology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for Cardiology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Autoimmune Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for Autoimmune Diseases Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World 6-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World 6-Year Perspective for Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 22: World 6-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 25: World Biomarker Clinical Phase Outsourcing Services Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 46: China Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • FRANCE
    • Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 60: France Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 78: UK Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제